John M. Pagel

23.2k total citations · 4 hit papers
286 papers, 9.3k citations indexed

About

John M. Pagel is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, John M. Pagel has authored 286 papers receiving a total of 9.3k indexed citations (citations by other indexed papers that have themselves been cited), including 124 papers in Pathology and Forensic Medicine, 110 papers in Genetics and 85 papers in Oncology. Recurrent topics in John M. Pagel's work include Lymphoma Diagnosis and Treatment (124 papers), Chronic Lymphocytic Leukemia Research (103 papers) and Radiopharmaceutical Chemistry and Applications (59 papers). John M. Pagel is often cited by papers focused on Lymphoma Diagnosis and Treatment (124 papers), Chronic Lymphocytic Leukemia Research (103 papers) and Radiopharmaceutical Chemistry and Applications (59 papers). John M. Pagel collaborates with scholars based in United States, South Africa and Italy. John M. Pagel's co-authors include Klaus Giese, Rudolf Grosschedl, Oliver W. Press, Ajay K. Gopal, Frederick R. Appelbaum, Jennifer R. Brown, Brent L. Wood, William G. Wierda, Roland B. Walter and Ted Gooley and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

John M. Pagel

282 papers receiving 9.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

2015 1.3k citations Andrew W. Roberts, Matthew S. Davids et al. New England Journal of Medicine profile →
HMG domain proteins: architectural elements in the assembly of nucleoprotein structures

1994 695 citations John M. Pagel et al. profile →
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

2008 573 citations Brian G. Till, Michael C. Jensen et al. Blood profile →
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

2012 431 citations Brian G. Till, Michael C. Jensen et al. Blood profile →

Peers

Countries citing papers authored by John M. Pagel

Since Specialization

Citations

This map shows the geographic impact of John M. Pagel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John M. Pagel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John M. Pagel more than expected).

Fields of papers citing papers by John M. Pagel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John M. Pagel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John M. Pagel. The network helps show where John M. Pagel may publish in the future.

Co-authorship network of co-authors of John M. Pagel

This figure shows the co-authorship network connecting the top 25 collaborators of John M. Pagel. A scholar is included among the top collaborators of John M. Pagel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John M. Pagel. John M. Pagel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203 2024 ·Leukemia ·(unknown), Megan Othus, (unknown), Harry P. Erba, Guillermo Garcia‐Manero, John M. Pagel, Mohamed L. Sorror, Mary‐Elizabeth M. Percival	0
2	Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors 2023 ·Clinical Cancer Research ·Johnnie J. Orozco, (unknown), Ted Gooley, (unknown), (unknown), (unknown), D. Scott Wilbur, Manuela C. Matesan, Darrell R. Fisher, Ajay K. Gopal, Damian J. Green, John M. Pagel, Brenda M. Sandmaier	2
3	Current and future treatment strategies in chronic lymphocytic leukemia 2021 ·Journal of Hematology & Oncology ·Krish Patel, John M. Pagel	43
4	Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study 2021 ·Blood Advances ·Gareth P. Gregory, Shaji Kumar, Ding Wang, Daruka Mahadevan, Patricia Walker, Nina D. Wagner‐Johnston, Carolina Escobar, Rajat Bannerji, Divaya Bhutani, Julie Chang, Francisco J. Hernandez‐Ilizaliturri, Andreas K. Klein, John M. Pagel, Witold B. Rybka, Andrew J. Yee, (unknown), Mo Huang, Mohammed Farooqui, Patricia Marinello, Hang Quach	24
5	Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA 2020 ·Molecular Cancer Therapeutics ·Johnnie J. Orozco, Aimee L. Kenoyer, Yukang Lin, Shyril O’Steen, (unknown), (unknown), (unknown), Mark D. Hylarides, Darrell R. Fisher, (unknown), Donald K. Hamlin, D. Scott Wilbur, Kelly Davis Orcutt, K. Dane Wittrup, Damian J. Green, Ajay K. Gopal, Brian G. Till, Brenda M. Sandmaier, Oliver W. Press, John M. Pagel	8
6	Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib 2019 ·Blood Advances ·Farrukh T. Awan, Anna Schuh, Jennifer R. Brown, Richard R. Furman, John M. Pagel, Peter Hillmen, Deborah M. Stephens, Jennifer A. Woyach, Елена Бибикова, Prista Charuworn, Melanie M. Frigault, Ahmed Hamdy, Raquel Izumi, Bolan Linghu, Priti Patel, Min Hui Wang, John C. Byrd	144
7	Phase I Study of a CD45-Targeted Antibody–Radionuclide Conjugate for High-Risk Lymphoma 2019 ·Clinical Cancer Research ·Ryan D. Cassaday, Oliver W. Press, John M. Pagel, Joseph G. Rajendran, Ted Gooley, Darrell R. Fisher, Leona Holmberg, Robert S. Miyaoka, Brenda M. Sandmaier, Damian J. Green, Ajay K. Gopal	16
8	KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study 2019 ·Blood ·Michael Wang, Javier Muñoz, André Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter A. McSweeney, David B. Miklos, John M. Pagel, Marie José Kersten, Weimin Peng, Lianqing Zheng, John M. Rossi, Rajul K. Jain, Arati V. Rao, Patrick M. Reagan	18
9	Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia 2016 ·British Journal of Haematology ·Tadeusz Robak, Andrzej Hellmann, Janusz Kłoczko, Javier Loscertales, Ewa Lech‐Marańda, John M. Pagel, Anthony R. Mato, John C. Byrd, Farrukh T. Awan, Holger Hebart, (unknown), Brian T. Hill, Michael Hallek, Amy J. Eisenfeld, Scott Stromatt, Ulrich Jaeger	30
10	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia breakdown → 2015 ·New England Journal of Medicine ·Andrew W. Roberts, Matthew S. Davids, John M. Pagel, Brad S. Kahl, Soham D. Puvvada, John F. Gerecitano, Thomas J. Kipps, Mary Ann Anderson, Jennifer R. Brown, Lori A. Gressick, Shekman Wong, Martin Dunbar, Ming Zhu, Monali Desai, Elisa Cerri, Sari H. Enschede, Rod Humerickhouse, William G. Wierda, John F. Seymour	1337
11	In Vivo Localization of 90Y and 177Lu Radioimmunoconjugates Using Cerenkov Luminescence Imaging in a Disseminated Murine Leukemia Model 2014 ·Cancer Research ·(unknown), Aimee L. Kenoyer, Johnnie J. Orozco, (unknown), Mazyar Shadman, Darrell R. Fisher, Damian J. Green, Mark D. Hylarides, Oliver W. Press, D. Scott Wilbur, John M. Pagel	19
12	A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies 2013 ·Cancer Research ·Damian J. Green, Nural Orgun, Jon C. Jones, Mark D. Hylarides, John M. Pagel, Donald K. Hamlin, D. Scott Wilbur, Yukang Lin, Darrell R. Fisher, Aimee L. Kenoyer, Shani L. Frayo, Ajay K. Gopal, Johnnie J. Orozco, Theodore A. Gooley, Brent L. Wood, William Bensinger, Oliver W. Press	40
13	Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model 2013 ·Blood ·Johnnie J. Orozco, Tom Bäck, Aimee L. Kenoyer, (unknown), Donald K. Hamlin, D. Scott Wilbur, Darrell R. Fisher, Shani L. Frayo, Mark D. Hylarides, Damian J. Green, Ajay K. Gopal, Oliver W. Press, John M. Pagel	54
14	Brentuximab Vedotin Administered To Platinum-Refractory Transplant Naïve Hodgkin Lymphoma Patients Can Increase The Proportion Achieving FDG-PET Negative Status 2013 ·Blood ·Maika Onishi, Leona Holmberg, Andrei R. Shustov, (unknown), (unknown), Mary Philip, Edward N. Libby, Ryan D. Cassaday, John M. Pagel, David G. Maloney, Damian J. Green, Brian G. Till, Oliver W. Press, Ajay K. Gopal	2
15	A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders 2012 ·Clinical Cancer Research ·John M. Timmerman, John C. Byrd, David Andorsky, Reiko Yamada, Janet Kramer, Natarajan Muthusamy, Naomi Hunder, John M. Pagel	53
16	CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results breakdown → 2012 ·Blood ·Brian G. Till, Michael C. Jensen, Jinjuan Wang, Xiaojun Qian, Ajay K. Gopal, David G. Maloney, Catherine Lindgren, Yukang Lin, John M. Pagel, Lihua E. Budde, Andrew Raubitschek, Stephen J. Forman, Philip D. Greenberg, Stanley R. Riddell, Oliver W. Press	431
17	Pretargeted Radioimmunotherapy Using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma 2011 ·Clinical Cancer Research ·Steven Park, (unknown), (unknown), Donald K. Hamlin, Yukang Lin, D. Scott Wilbur, Patrick S. Stayton, Nural Orgun, Mark D. Hylarides, Franz Buchegger, Aimee L. Kenoyer, (unknown), Ajay K. Gopal, Damian J. Green, John M. Pagel, Oliver W. Press	27
18	Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia: Relapse-Free Survival Is Determined by Karyotype and Comorbidities 2010 ·Biology of Blood and Marrow Transplantation ·Hesham Eissa, Ted Gooley, Mohamed L. Sorror, (unknown), Bart L. Scott, K Doney, Keith R. Loeb, Paul J. Martin, John M. Pagel, Jerry Radich, Brenda M. Sandmaier, Edus H. Warren, Rainer Storb, Frederick R. Appelbaum, H. Joachim Deeg	81
19	Biodistributions, Myelosuppression, and Toxicities in Mice Treated with an Anti-CD45 Antibody Labeled with the α-Emitting Radionuclides Bismuth-213 or Astatine-211 2009 ·Cancer Research ·Hirohisa Nakamae, D. Scott Wilbur, Donald K. Hamlin, Monica S. Thakar, Erlinda B. Santos, Darrell R. Fisher, Aimee L. Kenoyer, John M. Pagel, Oliver W. Press, Rainer Storb, Brenda M. Sandmaier	43
20	Extracorporeal Adsorption Therapy: A Method to Improve Targeted Radiation Delivered by Radiometal-Labeled Monoclonal Antibodies 2008 ·Cancer Biotherapy and Radiopharmaceuticals ·Eneida R. Nemecek, Damian J. Green, Darrell R. Fisher, John M. Pagel, Yukang Lin, Ajay K. Gopal, Lawrence D. Durack, Joseph G. Rajendran, D. Scott Wilbur, Rune Nilsson, Bengt Sandberg, Oliver W. Press	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact